deltatrials
Completed PHASE1 NCT00411866

Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812

Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg

Sponsor: GlaxoSmithKline

Conditions Schizophrenia
Interventions Ketoconazole SB773812
Updated 6 times since 2017 Last updated: Aug 2, 2017 Started: Oct 13, 2006 Primary completion: Oct 10, 2007 Completion: Oct 10, 2007

Listed as NCT00411866, this PHASE1 trial focuses on Schizophrenia and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2006, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Aug 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Aug 2017 [monthly]

    Completed PHASE1

    First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dundee, United Kingdom